Cinitapride monotartrate
Modify Date: 2024-02-04 19:55:31
Cinitapride monotartrate structure
|
Common Name | Cinitapride monotartrate | ||
|---|---|---|---|---|
| CAS Number | 1207859-16-2 | Molecular Weight | 552.57 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C25H36N4O10 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Cinitapride monotartrateCinitapride monotartrate is a 5-HT1A and 5-HT4 agonist. Cinitapride monotartrate is also a 5-HT2A and D2 antagonist. Cinitapride monotartrate can be used for the research of functional dyspepsia[1][2]. |
| Name | 4-amino-N-[1-(cyclohex-3-en-1-ylmethyl)piperidin-4-yl]-2-ethoxy-5-nitrobenzamide,(2R,3R)-2,3-dihydroxybutanedioic acid |
|---|---|
| Synonym | More Synonyms |
| Description | Cinitapride monotartrate is a 5-HT1A and 5-HT4 agonist. Cinitapride monotartrate is also a 5-HT2A and D2 antagonist. Cinitapride monotartrate can be used for the research of functional dyspepsia[1][2]. |
|---|---|
| Related Catalog | |
| Target |
5-HT2 Receptor 5-HT1 Receptor 5-HT4 Receptor D2 Receptor |
| In Vivo | Cinitapride (intraperitoneal injection; 0.25-1 mg/kg; once) shows gastroprotective effetcs in gastric ulceration rat model[2]. Animal Model: Male Wistar rats with gastric ulceration[2] Dosage: 0.25-1 mg/kg Administration: Intraperitoneal injection; 0.25-1 mg/kg; once Result: Reduced haemorrhagic lesions compared with the ulcerated control group. Decreased the percentage of ulceration to 28.76% at the highest dose (1 mg/kg). Attenuated the increase myeloperoxidase activity (p<0.05, p<0.01). Increased GSH-px activity in the gastric mucosa. |
| References |
| Molecular Formula | C25H36N4O10 |
|---|---|
| Molecular Weight | 552.57 |
| Exact Mass | 552.24300 |
| PSA | 231.96000 |
| LogP | 2.62070 |
| UNII-2Z90GEN540 |
| cinitapride tartrate |
| Cinitapride hygrogen tartrate |